Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.[10]
In December 2014, olaparib was approved for use as a single agent by the European Medicines Agency (EMA) in the European Union and by the Food and Drug Administration (FDA) in the United States.[11][12][13][14]
^"Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^"Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.
^"Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
^"Lynparza 50 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 7 October 2019. Archived from the original on 23 September 2020. Retrieved 13 April 2020.
^"Lynparza 100mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 7 October 2019. Retrieved 13 April 2020.
^Cite error: The named reference Lynparza capsule PI was invoked but never defined (see the help page).
^Cite error: The named reference Lynparza FDA label was invoked but never defined (see the help page).
^"Lynparza EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 6 October 2020.
^Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. (July 2009). "Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers". The New England Journal of Medicine. 361 (2): 123–134. doi:10.1056/NEJMoa0900212. PMID 19553641.
^"Lynparza (olaparib): An overview of Lynparza and why it is authorised in the EU" (PDF). European Medicines Agency (EMA). Archived from the original (PDF) on 16 March 2018. Retrieved 13 April 2020.
^"Lynparza EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 13 April 2020.
^"Drug Approval Package: Lynparza (olaparib) Capsules NDA #206162". U.S. Food and Drug Administration (FDA). 22 January 2015. Retrieved 13 April 2020.
^"FDA approves Lynparza to treat advanced ovarian cancer". U.S. Food and Drug Administration (FDA) (Press release). 19 December 2014. Archived from the original on 19 December 2014. Retrieved 30 December 2019. This article incorporates text from this source, which is in the public domain.
Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a...
for long-term neurodegenerative diseases. Olaparib: In December, 2014, the EMA and US FDA approved olaparib as monotherapy (at 400 mg taken twice per...
Fleming GF, et al. (October 2014). "Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer:...
mutations. Talazoparib is similar to the first in class PARP inhibitor, olaparib. The most common adverse reactions of any grade were fatigue, anemia, nausea...
treatments for astrocytoma and as the first-line treatment for glioblastoma. Olaparib in combination with temozolomide demonstrated substantial clinical activity...
small-molecule drugs or monoclonal antibodies, and PARP inhibitors such as olaparib. Other therapies include hyperthermia, immunotherapy, photodynamic therapy...
Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III...
with chemotherapies (paclitaxel, docetaxel, gemcitabine, and irinotecan), olaparib, erlotinib, venetoclax, and rituximab in advanced hematological malignancies...
platinum-sensitive recurrences is olaparib, which may improve progression-free survival but has not been shown to improve overall survival. (Olaparib, a PARP inhibitor...
for those with mutations activating the protein PIK3CA. PARP inhibitors (olaparib and talazoparib) for those with mutations that inactivate BRCA1 or BRCA2...
FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Metastatic Breast Cancer | Myriad Genetics, Inc". investor...
million. In December, the company received accelerated FDA approval for Olaparib in the treatment of women with advanced ovarian cancer who have a BRCA...
immune checkpoint inhibitor drug pembrolizumab and PARP inhibitors, namely olaparib, rucaparib, or niraparib. Bone metastases – present in around 85% of those...
Global Information
(what is this?) (verify)
This article incorporates text from this source, which is in the public domain.
